Jeffrey S. Farrow - 05 Mar 2026 Form 4 Insider Report for Tarsus Pharmaceuticals, Inc. (TARS)

Role
Chief Financial Officer and Chief Strategy Officer
Signature
/s/ Jeffrey Farrow
Issuer symbol
TARS
Transactions as of
05 Mar 2026
Net transactions value
$0
Form type
4
Filing time
09 Mar 2026, 16:06:51 UTC
Previous filing
18 Jun 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Farrow Jeffrey S Chief Financial Officer and Chief Strategy Officer C/O TARSUS PHARMACEUTICALS, INC., 15440 LAGUNA CANYON ROAD, SUITE 160, IRVINE /s/ Jeffrey Farrow 09 Mar 2026 0001405253

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TARS Stock Option (right to buy) Award +30,724 $0.000000* 30,724 05 Mar 2026 Common Stock 30,724 $74.90 Direct F1
transaction TARS Restricted Stock Units Award +19,306 $0.000000* 19,306 05 Mar 2026 Common Stock 19,306 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 25% of the option shares shall vest on March 5, 2027, and 1/48th of the option shares shall vest each month thereafter for a period of 3 years, subject to the Reporting Person's continuous service.
F2 Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock.
F3 The RSUs will vest in four equal annual installments on March 15th of each of 2027, 2028, 2029, and 2030, subject to the Reporting Person's continuous service.

Remarks:

Chief Financial Officer and Chief Strategy Officer